Shares of Sangamo Therapeutics, Inc. (NASDAQ: SGMO) were down 10.5% as of 3:34 p.m. EDT on Thursday. This marked the second consecutive day of double-digit percentage declines following the biotech’s interim update from a phase 1/2 clinical study evaluating SB-913 in treating Hunter syndrome, which is also known as mucopolysaccharidosis type II (MPS II). Sangamo’s update disappointed investors because SB-913 didn’t demonstrate solid efficacy.
There are two primary reasons why the SB-913 interim update was such a letdown for investors. First, the study is the first to use zinc-finger nuclease (ZFN) in vivo (inside the body) gene editing in humans. There were high expectations that Sangamo’s ZFN approach would be overwhelmingly effective. That wasn’t the case.
The other reason the disappointment was so intense is that SB-913 is one of three Sangamo ZFN therapies that are currently in early-stage clinical studies. A failure in treating Hunter syndrome could hint at problems for the biotech’s prospects in using ZFN to treat hemophilia B and MPS I.
However, Sangamo’s update didn’t contain all bad news. The biotech administered a larger dose of SB-913 to a second patient cohort and is cautiously optimistic about the results seen thus far. Sangamo gave an even higher dose to a third cohort of patients. Also, it’s important to note that we’re only talking about two patients in the first cohort who didn’t meet expectations.
It’s simply too early to know for sure if SB-913 will be effective. And it’s way too early to know if problems with this therapy will translate to issues for Sangamo’s other ZFN candidates.
Meanwhile, Sangamo is working with Pfizer on a phase 1 study of a gene therapy (which doesn’t involve actual editing of a gene like ZFN does) to treat hemophilia A. The company is also partnering with Bioverativ, which was acquired earlier this year by Sanofi, on a phase 1 study of a ZFN-based cell therapy targeting treatment of rare blood disorder beta thalassemia.
Sangamo is a risky stock — as all clinical-stage biotechs are, especially those with less advanced pipeline candidates. Most investors will probably want to watch from the sidelines for now. However, for those who are already Sangamo shareholders, I don’t think the disappointing news this week is enough to warrant throwing in the towel on the biotech stock.
10 stocks we like better than Sangamo Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and Sangamo Therapeutics wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018